by
Gus Iversen, Editor in Chief | September 17, 2025
Eli Lilly and Company plans to build a $5 billion manufacturing site in Goochland County, Virginia, marking the first of four domestic expansions the company expects to announce this year.
The facility will focus on producing active pharmaceutical ingredients (APIs) and drug products for cancer, autoimmune disorders and other advanced therapies.
The Indianapolis-based drugmaker said the site will be its first U.S. facility dedicated to both API production and finished drug manufacturing for its monoclonal antibody and bioconjugate portfolio, including antibody-drug conjugates (ADCs).
Ad Statistics
Times Displayed: 5266
Times Visited: 18 Brand-New FDA-cleared Advanced Ultrasound Medical Device available for sale or lease to Wound Care Centers or any other Medical Facilities.The Arobella 1000D is designed for non-contact or debridement ultrasound wound healing therapy, or any other wounds
Lilly expects the site to be operational within five years. Once completed, the facility is projected to create more than 650 full-time jobs in Virginia, spanning engineering, scientific, operations and lab roles. An additional 1,800 construction jobs are anticipated during the buildout.
"This investment in Virginia underscores our commitment to U.S. innovation and manufacturing — creating high-quality jobs, strengthening communities and advancing the health and well-being of Americans nationwide," said David A. Ricks, Lilly chair and CEO.
The Virginia project is part of Lilly’s broader $50 billion capital investment initiative in the U.S. since 2020. Company officials say the new facility will support a more resilient domestic supply chain, particularly in light of growing demand for complex biologic therapies.
Goochland County was selected based on workforce potential, infrastructure availability, zoning readiness and other local incentives. The company noted plans to incorporate digital systems, machine learning and AI to support efficient operations, and said it will partner with local universities and workforce programs for talent development.
“This isn’t just another manufacturing site, it represents a significant milestone for Lilly, as we begin building our first bioconjugate facility,” said Edgardo Hernandez, executive vice president and president of Lilly manufacturing operations.
The company expects to name the remaining three U.S. manufacturing sites by the end of the year.
